Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4911-4919

  Lupien, Andréanne ^a   Billal, Dewan S ^a,c   Fani, Fereshteh ^a   Soualhine, Hafid ^a,d   Zhanel, George G ^b   Leprohon, Philippe ^a   Ouellette, Marc ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CIPROFLOXACIN; CLOPIDOGREL; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; QUINOLONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESERPINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; EFFUSION; GENE DISRUPTION; GENE SEQUENCE; GENETIC TRANSFORMATION; GENOME; IN VITRO STUDY; MUTANT; MUTATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUMP; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; GENOME, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE;

EID: 84884243041     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00418-13     Document Type: Article

References (54)

1. Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman KP, Madhi SA, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott JA, Sow S, Whitney CG, Cutts F. 2006. Pneumococcal vaccination in developing countries. Lancet 367:1880-1882.
2. Liñares J, Ardanuy C, Pallares R, Fenoll A. 2010. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin. Microbiol. Infect. 16:402-410.
3. Zhanel GG, Karlowsky JA, Palatnick L, Vercaigne L, Low DE, Hoban DJ. 1999. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group. Antimicrob. Agents Chemother. 43:2504-2509.
4. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. 2009. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin. Infect. Dis. 48: e23-e33. doi:10.1086/595857.
5. Imai S, Ito Y, Ishida T, Hirai T, Ito I, Maekawa K, Takakura S, Iinuma Y, Ichiyama S, Mishima M. 2009. High prevalence of multidrug-resistant pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with communityacquired pneumonia in Japan. Clin. Microbiol. Infect. 15:1039-1045.
6. Sadowy E, Kuch A, Gniadkowski M, Hryniewicz W. 2010. Expansion and evolution of the Streptococcus pneumoniae Spain9V-ST156 clonal complex in Poland. Antimicrob. Agents Chemother. 54:1720-1727.
7. Patel SN, McGeer A, Melano R, Tyrrell GJ, Green K, Pillai DR, Low DE. 2011. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob. Agents Chemother. 55:3703-3708.
8. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ. 2002. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62:13-59.
9. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. 2009. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int. J. Antimicrob. Agents 34:82-85.
10. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. 2005. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis. 51:31-37.
11. Hooper DC. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist. Updat. 2:38-55.
12. Drlica K, Zhao X. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
13. Morrissey I, Farrell DJ, Bakker S, Buckridge S, Felmingham D. 2003. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or-susceptible Streptococcus pneumoniae from Hong Kong. Antimicrob. Agents Chemother. 47:1433-1435.
14. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. 2002. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 50(Suppl S1):25-37.
15. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. 2001. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl 2):S81-S93.
16. Fuller JD, Low DE. 2005. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41:118-121.
17. de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Perez-Trallero E, Linares J. 2004. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg. Infect. Dis. 10:1751-1759.
18. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
19. Stewart BA, Johnson AP, Woodford N. 1999. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin. J. Med. Microbiol. 48:1103-1106.
20. Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, Kohrer K, Schmitz FJ. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466.
21. Broskey J, Coleman K, Gwynn MN, McCloskey L, Traini C, Voelker L, Warren R. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl 1):95-99.
22. Weigel LM, Anderson GJ, Facklam RR, Tenover FC. 2001. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:3517-3523.
23. Perichon B, Tankovic J, Courvalin P. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.
24. Pan XS, Ambler J, Mehtar S, Fisher LM. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
25. Fukuda H, Hiramatsu K. 1999. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:410-412.
26. Fisher LM, Gould KA, Pan XS, Patel S, Heaton VJ. 2003. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J. Antimicrob. Chemother. 52:312-313; author's reply, 313-314.
27. Pan XS, Fisher LM. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
28. Brenwald NP, Gill MJ, Wise R. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
29. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. 2003. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:1867-1874.
30. Garvey MI, Baylay AJ, Wong RL, Piddock LJ. 2011. Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 55:190-196.
31. Zhanel GG, Hoban DJ, Schurek K, Karlowsky JA. 2004. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 24:529-535.
32. Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL. 2006. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:310-317.
33. Gill MJ, Brenwald NP, Wise R. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
34. Piddock LJ, Johnson MM, Simjee S, Pumbwe L. 2002. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and-susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:808-812.
35. El Garch F, Lismond A, Piddock LJ, Courvalin P, Tulkens PM, Van Bambeke F. 2010. Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:2076-2082.
36. Robertson GT, Doyle TB, Lynch AS. 2005. Use of an efflux-deficient Streptococcus pneumoniae strain panel to identify ABC-class multidrug transporters involved in intrinsic resistance to antimicrobial agents. Antimicrob. Agents Chemother. 49:4781-4783.
37. Boncoeur E, Durmort C, Bernay B, Ebel C, Di Guilmi AM, Croize J, Vernet T, Jault JM. 2012. PatA and PatB form a functional heterodimeric ABC multidrug efflux transporter responsible for the resistance of Streptococcus pneumoniae to fluoroquinolones. Biochemistry 51:7755-7765.
38. Fani F, Leprohon P, Legare D, Ouellette M. 2011. Whole genome sequencing of penicillin-resistant Streptococcus pneumoniae reveals mutations in penicillin-binding proteins and in a putative iron permease. Genome Biol. 12:R115. doi:10.1186/gb-2011-12-11-r115.
39. Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Legare D, Ouellette M. 2009. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 19:1214-1223.
40. Billal DS, Feng J, Leprohon P, Legare D, Ouellette M. 2011. Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics 12:512. doi:10.1186/1471-2164-12-512.
41. Claverys JP, Dintilhac A, Pestova EV, Martin B, Morrison DA. 1995. Construction and evaluation of new drug-resistance cassettes for gene disruption mutagenesis in Streptococcus pneumoniae, using an ami test platform. Gene 164:123-128.
42. Buckley ND, Lee LN, LeBlanc DJ. 1995. Use of a novel mobilizable vector to inactivate the scrA gene of Streptococcus sobrinus by allelic replacement. J. Bacteriol. 177:5028-5034.
43. Hakenbeck R, Balmelle N, Weber B, Gardes C, Keck W, de Saizieu A. 2001. Mosaic genes and mosaic chromosomes: intra-and interspecies genomic variation of Streptococcus pneumoniae. Infect. Immun. 69: 2477-2486.
44. Marrer E, Schad K, Satoh AT, Page MG, Johnson MM, Piddock LJ. 2006. Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:685-693.
45. Purich DL, Allison RD. 2000. Handbook of biochemical kinetics: a guide to dynamic processes in the molecular life sciences. Academic Press, San Diego, CA.
46. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810.
47. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. 2006. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe, including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn. Microbiol. Infect. Dis. 55:119-127.
48. Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, de Azavedo JC. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44: 3049-3054.
49. Canton R, Morosini M, Enright MC, Morrissey I. 2003. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52:944-952.
50. Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. 1999. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob. Agents Chemother. 43:329-334.
51. Davies TA, Goldschmidt R, Pfleger S, Loeloff M, Bush K, Sahm DF, Evangelista A. 2003. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J. Antimicrob. Chemother. 52:168-175.
52. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. 2005. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin. Infect. Dis. 40:225-235.
53. Dawson RJ, Locher KP. 2006. Structure of a bacterial multidrug ABC transporter. Nature 443:180-185.
54. Cabiscol E, Tamarit J, Ros J. 2000. Oxidative stress in bacteria and protein damage by reactive oxygen species. Int. Microbiol. 3:3-8.